Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct 20:6:282.
doi: 10.3389/fnagi.2014.00282. eCollection 2014.

Nutrition and prevention of Alzheimer's dementia

Affiliations
Review

Nutrition and prevention of Alzheimer's dementia

Arun Swaminathan et al. Front Aging Neurosci. .

Abstract

A nutritional approach to prevent, slow, or halt the progression of disease is a promising strategy that has been widely investigated. Much epidemiologic data suggests that nutritional intake may influence the development and progression of Alzheimer's dementia (AD). Modifiable, environmental causes of AD include potential metabolic derangements caused by dietary insufficiency and or excess that may be corrected by nutritional supplementation and or dietary modification. Many nutritional supplements contain a myriad of health promoting constituents (anti-oxidants, vitamins, trace minerals, flavonoids, lipids, …etc.) that may have novel mechanisms of action affecting cellular health and regeneration, the aging process itself, or may specifically disrupt pathogenic pathways in the development of AD. Nutritional modifications have the advantage of being cost effective, easy to implement, socially acceptable and generally safe and devoid of significant adverse events in most cases. Many nutritional interventions have been studied and continue to be evaluated in hopes of finding a successful agent, combination of agents, or dietary modifications that can be used for the prevention and or treatment of AD. The current review focuses on several key nutritional compounds and dietary modifications that have been studied in humans, and further discusses the rationale underlying their potential utility for the prevention and treatment of AD.

Keywords: Alzheimer; clinical trial; nutrition; prevention; treatment.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Diagram of multiple influences of dietary constituents on cellular pathways and process linked to neurodegeneration in AD. Antioxidants, trace minerals, flavonoids, metabolic substrates and modulators, vitamins, and omega-3 fatty acids, among others, have all been shown to downregulate the many pathological processes linked to the development of AD, including aging, amyloid deposition, neurofibrillary degeneration, synapse loss, inflammation, metabolic compromise, loss of vascular integrity, and neuronal injury and loss. Note: specific dietary factors may have more than one potential mechanism of action on the pathogenic processes contributing to neurodegeneration in AD. Links between pathological processes implicated in the development of AD may not be linear, but rather additive and are shown in a circular fashion without implication for specific linkages or temporal associations between such processes.

Similar articles

Cited by

References

    1. Aggarwal B. B. (2010). Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu. Rev. Nutr. 30 173–199. 10.1146/annurev.nutr.012809.104755 - DOI - PMC - PubMed
    1. Aisen P. S., Schneider L. S., Sano M., Diaz-Arrastia R., van Dyck C. H., Weiner M. F., et al. (2008). High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 300 1774–1783. 10.1001/jama.300.15.1774 - DOI - PMC - PubMed
    1. Anekonda T. S. (2006). Resveratrol – a boon for treating Alzheimer’s disease? Brain Res. Rev. 52 316–326. 10.1016/j.brainresrev.2006.04.004 - DOI - PubMed
    1. Anekonda T. S., Reddy P. H. (2006). Neuronal protection by sirtuins in Alzheimer’s disease. J. Neurochem. 96 305–313. 10.1111/j.1471-4159.2005.03492.x - DOI - PubMed
    1. Baum L., Lam C. W., Cheung S. K., Kwok T., Lui V., Tsoh J., et al. (2008). Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J. Clin. Psychopharmacol. 28 110–113. 10.1097/jcp.0b013e318160862c - DOI - PubMed

LinkOut - more resources